The 2023 Georgia Life Science Summit is Nov. 1, 2023

The state’s premier life sciences gathering for over three decades, Georgia Bio proudly presents the 2023 Georgia Life Science Summit on Wednesday, November 1, 2023 at the Sandy Springs Arts Center.

Dr. Ted W. Love headshot

The 2023 summit, more concentrated in scope yet expansive in industry inclusion, will be Wednesday, November 1st at the Sandy Springs Arts Center. The program is coming along nicely including a recently secured keynote address and chat featuring Dr. Ted W. Love , former President and CEO of Global Blood Therapeutics and 2023-2025 Chair of the Board of the Biotechnology Innovation Organization (BIO).

Other program elements including speakers / presenters currently include:

  • Patricia Obermaier, Chief Growth Officer, Global Health and Life Sciences, Microsoft
  • Dr. Joe Sutherland, Director, Center for AI Learning, Emory University
  • The Intersection of Software and Science – A Plenary Session
  • Launching and Funding a Company in a Challenging Environment: Investors’ Perspectives of Best Practices and Critical Errors – A Plenary Session
  • Life Sciences Showcase – Hear Georgia-based companies who are developing or have bioscience/medtech related products present their technology. (Winners announced during the closing session)
  • Plenty of dedicated networking time and a closing reception with light food and beverages.

We encourage you to join us in reconnecting with the life science industry ecosystem. 

Learn more and register here .

In the meantime, please know we are working diligently and with strong industry support to accomplish the following: rebuild trust with industry, strengthen brand awareness, simplify our message and respond to industry demand for a stronger unified voice on behalf of industry for policy priorities.

“Georgia Bio is recommitting to its core mission of advocating for, connecting, educating and inspiring our member enterprises and stakeholders in much the same way our colleagues have known Georgia Bio since its inception in 1989,” Georgia Bio CEO Maria Thacker said. “We will now do that through an industry-wide lens more inclusive of new medical technologies and devices, and food and ag innovations. We expect the 2023 Summit to be a high value, enthusiastic event for all of our participants and stakeholders.”

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS